Prognostic value of aspartate aminotransferase/alanine aminotransferase ratio in hepatocellular carcinoma after hepatectomy

Rong-Rui Huo,Li-Xin Pan,Pei-Sheng Wu,Xiu-Mei Liang,Xue-Mei You,Liang Ma,Jian-Hong Zhong

DOI: https://doi.org/10.1093/bjsopen/zrad155

2024-01-03

BJS Open

Abstract:Abstract Background The prognostic significance of the aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio in hepatocellular carcinoma remains uncertain. The aim of the current study was to evaluate the association between the AST/ALT ratio and prognosis in patients with hepatocellular carcinoma after hepatectomy, and to explore the role of underlying liver diseases as mediators. Methods This retrospective study included patients with hepatocellular carcinoma who underwent hepatectomy between January 2014 and January 2018 at two Chinese hospitals. The maximally selected rank statistic and g-computation approach were used to quantify and visualize the association between the AST/ALT ratio and overall survival or recurrence-free survival. The role of mediators (chronic hepatitis B, hepatic steatosis and liver cirrhosis) was analysed. Results Among the 1519 patients (mean(s.d.) age at baseline, 50.5(11.3) years), 1309 (86.2%) were male. During a median follow-up of 46.0 months, 514 (33.8%) patients died and 358 (23.6%) patients experienced recurrence. The optimal cut-off value for the AST/ALT ratio was 1.4, and the AST/ALT ratio greater than or equal to 1.4 was independently associated with a 39.0% increased risk of death and a 30.0% increased risk of recurrence (overall survival: hazard ratio (HR), 1.39; 95% c.i. 1.15 to 1.68; recurrence-free survival: HR, 1.30; 95% c.i. 1.12 to 1.52) after adjusting for confounders. Chronic hepatitis B significantly mediated the association of the ratio of AST/ALT with both overall survival and recurrence-free survival (20.3% for overall survival; 20.1% for recurrence-free survival). Conclusion The AST/ALT ratio greater than or equal to 1.4 was associated with shorter overall survival and recurrence-free survival in patients with hepatocellular carcinoma after hepatectomy, and chronic hepatitis B may play a role in their association.

surgery

What problem does this paper attempt to address?

The paper aims to explore the significance of the aspartate aminotransferase to alanine aminotransferase ratio (AST/ALT) in the prognosis of hepatocellular carcinoma (HCC) patients after liver resection and to investigate the role of potential liver diseases (such as chronic hepatitis B, fatty liver, and cirrhosis) as mediating factors.

Specifically, the main objective of the study is to evaluate the association between the AST/ALT ratio and overall survival (OS) and recurrence-free survival (RFS) in HCC patients. By retrospectively analyzing the clinical data of 1519 HCC patients who underwent liver resection in two hospitals in China from January 2014 to January 2018, the study found:

1. **AST/ALT Ratio**:
- The optimal cutoff point is 1.4.
- An AST/ALT ratio greater than or equal to 1.4 is significantly associated with shorter overall survival and recurrence-free survival.
- After adjusting for confounding factors, patients with an AST/ALT ratio greater than or equal to 1.4 had a 39% increased risk of death and a 30% increased risk of recurrence.

2. **Mediation Analysis**:
- Chronic hepatitis B plays a significant mediating role in the relationship between the AST/ALT ratio and overall survival and recurrence-free survival (20.3% and 20.1%, respectively).
- Fatty liver and cirrhosis were not found to be mediating factors.

In summary, an AST/ALT ratio greater than or equal to 1.4 is associated with poorer prognosis in HCC patients after liver resection, and chronic hepatitis B may mediate this association.